Alpha Compute: $21 Million NTM Sales Outlook Shows Scale-Up Potential – Quarterly Update Report
ALPHA-01 validates customer demand, while ALPHA-02 and the expansion ROFRs create a visible roadmap from a 504-GPU base…
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
MannKind MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation…